APN Trading Statement Neutral
ASPEN PHARMACARE HOLDINGS LIMITED - Business Update and Trading Statement for the six months ended 31 December 2025
Aspen Pharmacare Holdings Limited
Free preview
What this filing means
Bull case
- The core Commercial Pharmaceuticals segment achieved robust 4% revenue growth and double-digit constant exchange rate (CER) EBITDA growth, bolstered by strong demand for Mounjaro in SA.
- Strong balance sheet management with free cash flows expected to exceed R1.7 billion and net debt reduced to R28.6 billion (leverage <3.5x).
Bear case
- H1 2026 earnings face significant contraction, with HEPS expected to fall -33% to -38% and NHEPS down -19% to -24%.
Unlock the full analysis
Free during launch. Sign in to read the complete breakdown.
- Full bull / bear breakdown
- Decision framework
- Citations & sources
- Price autopsy
Related filings
More from APN
- ASPEN PHARMACARE HOLDINGS LIMITED - Notification in terms of Section 122 (3)(b) of the Companies Act and Section 6.54 of the JSE Listings Requirements
- ASPEN PHARMACARE HOLDINGS LIMITED - Dealing in Securities by a Prescribed Officer
- ASPEN PHARMACARE HOLDINGS LIMITED - Change in Chairmanship of the Audit and Risk Committee
- ASPEN PHARMACARE HOLDINGS LIMITED - Completion of the divestment of Aspen APAC
- ASPEN PHARMACARE HOLDINGS LIMITED - Dealing in Securities by a Director and Prescribed Officer
Other Trading Statement
- HDCHUDACO INDUSTRIES LIMITED - Trading Update and Trading Statement
- GOLDRUSH HOLDINGS LIMITED - Trading Statement for the financial year ended 31 March 2026
- TLMTELEMASTERS HOLDINGS LIMITED - Initial Trading Statement
- BELBELL EQUIPMENT LIMITED - Trading Statement
- SEBSEBATA HOLDINGS LIMITED - Trading Statement